AVDL Insider Trading Activity and SEC Form 4 Filings
AVDL insider trading summary
Over the past 12 months, insiders at Avadel Pharmaceuticals PLC (AVDL) reported 2 sales worth $466.7M by 2 insiders and no open-market purchases on SEC Form 4. Net insider selling was $466.7M.
Latest AVDL insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 13, 2026 | Andrew M Weiss | Insider | Sell | $233.4M (11,112,052 @ $21.00) |
| Feb 13, 2026 | Weiss Asset Management LP | Insider | Sell | $233.4M (11,112,052 @ $21.00) |
| Jan 21, 2025 | Linda Palczuk | Director | Buy | $40K (5,000 @ $7.93) |
| Jan 13, 2025 | Peter J. Thornton | Director | Buy | $80K (10,000 @ $8.04) |
| Jan 13, 2025 | Eric J Ende | Director | Buy | $235K (30,000 @ $7.84) |
| Dec 13, 2024 | Thomas S McHugh | Chief Financial Officer | Buy | $24K (2,300 @ $10.44) |
| Dec 11, 2024 | Thomas S McHugh | Chief Financial Officer | Buy | $52K (5,000 @ $10.49) |
| Dec 10, 2024 | Geoffrey Michael Glass | Director | Buy | $100K (10,075 @ $9.89) |
| Dec 10, 2024 | Geoffrey Michael Glass | Director | Buy | $100K (10,204 @ $9.80) |
| Dec 9, 2024 | Gregory J Divis | Chief Executive Officer | Buy | $4K (402 @ $9.82) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.